Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Apr 1;4(2):72-74.
doi: 10.1093/ehjcvp/pvy004.

How does the TRS 2°P score relate to real-world patients?

Marc P Bonaca  1 , Gaetano M De Ferrari  2 , Dan Atar  3 , Lori D Bash  4 , Dominik Lautsch  4 , Erin A Bohula  1 , Martin Horack  5 , Philippe Brudi  4 , Jean Ferrieres  6 , Anselm K Gitt  5   7
Affiliations
Editorial

How does the TRS 2°P score relate to real-world patients?

Marc P Bonaca et al. Eur Heart J Cardiovasc Pharmacother. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of TRS 2°P risk categories in IMPROVE-IT and DYSIS II CHD; LDL-C target attainment and lipid-lowering therapy according to TRS 2°P. Numbers below the graph refer to DYSIS II CHD; P-values were calculated using the Cochran–Armitage test for trend statin + ezetimibe combination and LDL-C <70 mg/dL (equal to <1.8 mmol/L), and the Jonckheere–Terpstra test for trend atorvastatin equivalents. LDL-C, LDL-cholesterol; KME, Kaplan–Meier estimates referring to the simvastatin-treated control group in IMPROVE-IT; CV, cardiovascular; Yr, year.
See this image and copyright information in PMC

References

    1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117–171. - PMC - PubMed
    1. Bohula EA, Bonaca MP, Braunwald E, Aylward PE, Corbalan R, De Ferrari GM, He P, Lewis BS, Merlini PA, Murphy SA, Sabatine MS, Scirica BM, Morrow DA.. Atherothrombotic risk stratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction. Circulation 2016;134:304–313. - PubMed
    1. Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park JG, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald E.. Atherothrombotic risk stratification and ezetimibe for secondary prevention. J Am Coll Cardiol 2017;69:911–921. - PubMed
    1. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM.. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387–2397. - PubMed
    1. Gitt AK, Ferrieres J, de Ferrari GM, Vyas A, Baxter C, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang F-T, Keong Poh K, Brudi P, Ambegaonakr BM.. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II. Atherosclerosis 2017;266:158–166. - PubMed

Publication types

Substances

LinkOut - more resources